<DOC>
	<DOCNO>NCT00634179</DOCNO>
	<brief_summary>This open-label ( doctor patient know drug give ) , single center , phase 1/2 clinical trial . The primary objective determine whether VR-CHOP provide benefit patient previously untreated indolent non-Hodgkin 's lymphoma ( NHL ) .</brief_summary>
	<brief_title>A Phase I/II Trial VR-CHOP Lymphoma Patients</brief_title>
	<detailed_description>This study ass whether add bortezomib ( Velcade ) R-CHOP ( new combination call VR-CHOP ) improve outcome patient indolent NHL previously receive treatment . Patients eligible take part study receive VR-CHOP dos Velcade vincristine establish phase 1 . Patients receive VR-CHOP 8 cycle treatment ( 21 day duration ) . During treatment , patient assess response therapy possible side effect . All patient go receive maintenance therapy completion initial treatment design protocol .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Tissue diagnosis previously untreated , cluster differentiation antigen 20+ ( CD20+ ) , Bcell nonHodgkin lymphoma . For Phase 1 trial : patient follow diagnosis eligible : Follicular Lymphomas ( Grade 1 , 2 , 3a , 3b ) Small Lymphocytic Lymphoma Marginal Zone Lymphomas For Phase 2 trial : patient follow diagnosis eligible : Follicular Lymphomas ( Grade 1 , 2 , 3a ) Small Lymphocytic Lymphoma Marginal Zone Lymphomas Patients follicular lowgrade lymphoma must indication treatment base modify Groupe d'Etude de Lymphomes Folliculaires ( GELF ) criteria Follicular Lymphoma International Prognostic Index ( FLIPI ) score ≥ 3 . Indications treatment base modify GELF criterion include one following : B symptom lymphomarelated symptoms Involvement 3 nodal site , diameter 3 cm Any nodal extranodal tumor mass diameter 7 cm Splenomegaly great 16 cm CT scan . Pleural effusion peritoneal ascites Cytopenias ( leukocytes &lt; 1.0 x 10 /L and/or platelet &lt; 100 x 10/L ) Leukemia ( &gt; 5.0 x 10 /L circulate malignant cell ) Indications treatment base FLIPI criterion include three follow : Age ≥ 60 year Ann Arbor stage III IV Hemoglobin level &lt; 120 g/L Number nodal area involve &gt; 4 Serum lactate dehydrogenase ( LDH ) level &gt; normal Only chemotherapynaïve subject eligible . Subjects may receive prednisone ( &lt; 2 month therapy ) radiation ≤ 2 site therapy . Voluntary write informed consent Health Insurance Portability Accountability Act ( HIPAA ) Authorization performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Female patient child bear potential must negative βhuman chorionic gonadotropin ( βhCG ) test . Male subject agrees use acceptable method contraception duration study . ≥ 18 year age time registration . Patients must adequate renal function demonstrate serum creatinine &lt; 1.5 mg/dl unless felt secondary lymphoma . Must alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) ≤ 3.5 upper limit normal total bilirubin ≤ 2.0 mg/dL unless secondary lymphoma . Must cardiac leave ventricular ejection fraction ≥ 50 % . At least 1 measurable tumor mass ( great 1.5 cm long dimension great 1.0 cm short axis ) . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Subject primary secondary central nervous system ( CNS ) lymphoma ( current previously treat ) eligible . A history unrelated ( nonlymphomatous ) neoplasm within past 10 year nonmelanoma skin cancer insitu cervix cancer . Subjects prior diagnosis malignancy 10 year may enter study discretion Principal Investigator . Serious medical psychiatric illness likely interfere participation clinical study . Patient receive investigational drug 14 day enrollment . Patient hypersensitivity boron mannitol . Female subject pregnant breastfeeding . Chemotherapeutic agent know teratogenic effect develop embryo cause chromosomal damage gamete . These agent also cause bone marrow suppression excrete milk . Confirmation subject pregnant must establish negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Patient ≥ Grade 2 peripheral neuropathy within 14 day enrollment . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Patient platelet count &lt; 10 x 10¹⁰/L ( unless due bone marrow involvement lymphoma document within 14 day enrollment ) . Patient absolute neutrophil count &lt; 1.0 x 10⁹/L ( unless due bone marrow involvement lymphoma document within 14 day enrollment ) . Patient calculate measured creatinine clearance &lt; 20 mL/minute within 14 day enrollment . Presence antibodies HIV . Subject unwilling give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lymphoma</keyword>
</DOC>